Evaluation of chemopreventive potential of xanthone from *Swertia chirata* against DMBA/croton oil-induced chemical carcinogenesis in Swiss mice

Atish Barua, Pritha Choudhury, Chinmay Kumar Panda and Prosenjit Saha*
Chittaranjan National Cancer Institute, Shyama Prasad Mukherjee Road, Bakul Bagan, Bhowanipore, Kolkata 700 026, India

The present study was designed to determine the chemopreventive efficiency of 1,5,8-trihydroxy-3-methoxy xanthone, abbreviated as TMX, isolated and purified from the aerial part of the plant *Swertia chirata* against 9,10-dimethylbenz[α]-anthracene (DMBA)/croton oil-induced skin cancer, and probe into the molecular mechanism. All the mice in the carcinogen control group developed severe dysplastic lesions after the 14th week of application of the carcinogen, which progressed to carcinoma *in situ* around the 20th week; this was validated histologically. However, after TMX treatment, only around 50% of mice developed papilloma which histologically was found to be restrictive to moderate to severe hyperplastic change in the 14th and 20th week. The chemopreventive potential was determined by calculating the attributable risk (AR), which was –11.3 for the 14th week and increased up to –17.5 for the 20th week. To ascertain the effect of TMX treatment on inflammation, the effect of TMX on inflammatory cytokines was studied by ELISA. It revealed a significant reduction in inflammation upon TMX treatment for the 20th week. As TMX could hold its chemopreventive potential up to the 20th week, the molecular mechanism of restriction was studied for the 20th week of treatment. Skin forms a rich source of stem cells which orchestrate the progression of carcinogenesis and become cancer stem cells (CSCs). β-Catenin and KRAS are known central modulators of CSCs, that play a crucial role in the progression of skin carcinogenesis. We observed that TMX treatment inhibited KRAS and nuclear translocation of β-catenin causing its cytoplasmic degradation by P-53 and P-21-mediated pathway, thereby exerting its chemopreventive potential.

**Keywords:** Attributable risk, carcinogenesis, chemopreventive efficiency, mice, *Swertia chirata*, xanthone.

Among the various models of chemical carcinogenesis, mouse skin is popular for the study of cellular and biochemical changes such as proliferation characterized by hyper proliferation, and culminating into full-blown carcinogenesis bearing the potential for invasion and metastasis,

One of the triggering events during initiation of carcinogenesis is the mutation to R as proto-oncogenes giving the cells selective growth advantage. Deregulation of the Wnt signalling pathway plays a deciding role in the modulation of multistage carcinogenesis. Deregulation of the Wnt ligands enables cytoplasmic degradation of β-catenin by forming a destruction complex, which is made up of adenomatous polyposis coli (APC), scaffold protein axin, casein kinase 1 (CK1) and glycogen synthase kinase 3β (GSK3β). Interaction of Wnt ligands with the receptor complex that comprises Frizzled/LRP5/LRP6 (low-density lipoprotein receptor-related protein), causes modulation of a series of downstream events, leading to its stabilization and ultimately nuclear translocation of β-catenin. Nuclear translocation of β-catenin modulates transcriptional regulation of multiple downstream oncogenic target genes involved in several process related to carcinogenesis. Mutations in APC and KRAS have been proven to play a crucial role in carcinogenesis and induction of metastasis through enrichment of cancer stem cell (CSC) population. GSK-3β causes proteasomal degradation of KRAS and β-catenin by polyubiquitination. We already know that upregulation of β-catenin causes upregulation of several inflammatory markers. Therefore, a molecule that could downregulate both β-catenin and KRAS is the need of the hour. As KRAS activation is considered to be one of the initiating events in skin cancer and skin being one of the sites where β-catenin-mediated self-renewal plays a crucial role in the maintenance of its property to self-renew, we have chosen the 9,10-dimethylbenz[a]-anthracene (DMBA)/croton oil-mediated skin carcinogenesis model to evaluate the effect and elucidate the mechanism of 1,5,8-trihydroxy-3-methoxy xanthone (TMX) as a chemopreventive agent. Among the xanthones from *Swertia chirata*, TMX was the most active, as it showed therapeutic activity at the lowest dosage of 20 μg/kg (ref. 10). Therefore, in this study, we examine the effect exerted by TMX on DMBA-mediated skin carcinogenesis and...
also analyse the molecular mechanism of chemoprevention, if any.

Materials

DMBA and croton oil and secondary antibodies were procured from Sigma Aldrich, St Louis, USA. Primary antibodies were procured from Santa Cruz Biotechnologies. RNA isolation, cDNA synthesis and real-time PCR kits were procured from Roche Diagnostics Pvt Ltd., Risch-Rotkreuz, Switzerland rest of the chemicals were procured locally and were of molecular biology-grade.

Isolation and purification of TMX from S. chirata

Extraction, purification and characterization of TMX were performed at the Department of Biochemistry, National Research Institute for Ayurvedic Drug Development, Kolkata, India. The process of isolation is patented vide Indian Patent No. 191129, dated 26 March 2002 (refs 11–13).

Animals for experimentation

Adult (5–6 weeks old) Swiss mice (25 ± 2 g body wt) were obtained from the animal house of Chittaranjan National Cancer Institute, Kolkata. They were kept in astringently regulated environment with temperature of 23° ± 2°C and humidity 55% ± 10% under strictly maintained alternating light and dark conditions of 12 h each. Animals were provided with a standard food pellet diet and filtered drinking water according to the CPCSEA guidelines. All experimental procedures were carried out strictly following the protocols adhering to CPCSEA guidelines, which were approved by the Institutional Animal Ethics Committee (IAEC; approval no. IAEC-1774/PS-1/2015/8).

Development of skin carcinogenesis by DMBA

The dorsal part of the skin of Swiss mice was shaved with an electric razor three days before starting of the experiment, as adopted from a previously established model in our department14. The specific dose of carcinogen DMBA was 1 mg/100 μl of acetone/mouse and promoter 1% croton oil application, which was done topically on the area that had been shaved. Time point of gradual development of skin carcinoma was established by observing histopathological changes, where the number of animals sacrificed at each time point was two and experiments were repeated thrice. The body weight of mice was recorded every week since the beginning of the study and continued till the end-point of the study. The animals were randomly divided into the following groups, where each group consisted of six animals and every experiment was repeated at least three times.

Normal control (NC): Neither carcinogen nor TMX was administered.

Carcinogen control (CC): Only carcinogen was administered as described in the graphical representation.

Continuous treatment (CT): TMX was administered two weeks prior to the first carcinogen administration and continued till the end-point of the study.

Cytoprotective effect of TMX against carcinogen-induced toxicity

In our study, blood was obtained by the method of cardiac puncture following the ethical guidelines from the animals of the experimental groups at the end of the experimental period of 20th week. The number of animals in each group were six, which was designated as \( n = 6 \). Serum was collected by separating from whole blood by following standard protocol of centrifugation at 2000 g for 15 min. Total blood parameters like counting of WBC, RBC, haemoglobin (HGB) and platelet (PLT) were measured from whole blood in an automated hematology analyzer (KX-21, Sysmex) following the manufacturer’s protocol.

Cytoprotective efficacy of TMX against carcinogen-induced toxicity was evaluated by analysis of liver and kidney toxicity parameters of mice from the experimental group at the end of the 20th week. Hepato- and nephrotoxicity parameters like the expression of ALT, AST, urea and creatinine were analysed using an automated analyser for clinical samples (AU400, Olympus, Tokyo, Japan) following the manufacturer’s guidelines (Olympus, Tokyo, Japan).

Phase-II antioxidative enzymes upon TMX treatment

Liver and skin samples were collected and lysates were prepared from liver and skin tissue obtained after sacrificing mice of the experimental group at the end of the experimental period, i.e. at the end of the 20th week. In the present study, the activity of phase-II detoxification enzymes like glutathione peroxidase (GPx), catalase (CAT), superoxide dismutase (SOD) and glutathione-S-transferase (GST) was measured in the skin and liver tissues of the mice from experimental groups of NC, CC and CT following previously described methods15–17.

Intracellular ROS generation

Liver and skin lysates were prepared from liver and skin tissue obtained after sacrificing mice of the experimental
group at the end of the 20th week. The relative level of reactive oxygen species (ROS) of skin and liver lysate was analysed by spectrofluorimetric method as described by Pal et al.14.

**Modulation of membrane peroxidation upon TMX treatment**

Hepatocytes and skin tissue were collected by sacrificing mice of the experimental group at the end of the experimental period (20th week). Lipid peroxidation (LPO) was estimated from the microsomal fraction extracted from hepatocytes and skin tissue lysates using thiobarbituric acid, and protein concentration was determined by a conventional method19. The representation was done by estimating the amount of thiobarbituric acid reactive substance (TBARS) formed per milligram protein using an extinction coefficient of $1.56 \times 10^7$ M$^{-1}$ cm$^{-1}$.

**Effect of TMX on inflammation and angiogenesis**

In the present study, the expression level of angiogenic and inflammatory markers was ascertained by ELISA. Blood was drawn from experimental mice by cardiac puncture and skin papillomas were collected after sacrifice of mice following ethical guidelines at the end of the 20th week. Serum was isolated from whole blood by a previously described method. Skin papillomas were made into single-cell suspension by finely mincing them in phosphate buffer saline and thereafter treatment with collagenase. Next, the samples were repeatedly passed through a syringe and a nylon mesh20.

The level of different pro- and anti-inflammatory markers such as IL-10, IL-1β, IL-6, IL-18 and angiogenic markers such as VEGF, MMP-2, MMP-9 was measured in blood serum and skin papilloma lysates by ELISA method (Jiangsu Keygen Biotech Corp Ltd), following the manufacturer's protocol21.

**Histopathological analysis of papilloma**

Three mice from each experimental group of NC, CC and CT were sacrificed according to the design of the experiment at two time points, i.e., 14th and 20th week. All the collected papilloma samples for each time point were fixed in 10% formaldehyde. Paraffin block for each papilloma
Table 1. Modulation of hematological and biochemical parameters upon TMX treatment of ascites-bearing mice

<table>
<thead>
<tr>
<th>Group</th>
<th>Hematological parameters</th>
<th>Biochemical parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>White blood cell (μl) × 10^3</td>
<td>Red blood cell (μl) × 10^6</td>
</tr>
<tr>
<td>Normal</td>
<td>15.6 (± 0.4)</td>
<td>4.69 (± 0.7)</td>
</tr>
<tr>
<td>Carcinogen control</td>
<td>87.8 (± 0.5)</td>
<td>2.12 (± 0.8)</td>
</tr>
<tr>
<td>TMX-treated</td>
<td>17.2 (± 0.2)**</td>
<td>5.05 (± 0.5)**</td>
</tr>
</tbody>
</table>

*Significant difference in the TMX-treated group in comparison with carcinogen control group considering P < 0.001. Values represent ± SEM of six samples in each group. IU, International unit.

Role of TMX on cellular apoptosis

This study validated apoptosis by TUNEL assay (Roche Molecular Biochemicals, Manheim, Germany) according to the manufacturer’s protocol. Data were acquired by visualizing the tissue sections under a bright-field microscope and the observations were validated by a pathologist.

Protein expression analysis

In this study, immunohistochemistry (IHC) was performed on skin tissue following a protocol established in our laboratory with slight modifications of the method described by Prince and Ginsberg. The protein expression pattern was scored according to Perrone et al. For immunoblot, total protein from skin tissue samples was extracted by sonication in RIPA buffer under chilled condition. The total protein lysate was resolved by SDS-PAGE. The immunoreactive protein bands on the membranes were visualized using chemiluminescence reagents (Millipore, Germany) in chemi-doc gel documentation (Biorad, USA).

mRNA expression analysis of different genes

RNA was isolated from skin tissue using Roche high-pure RNA isolation kit according to the manufacturer’s guide-lines. cDNA synthesis and real-time analysis were performed using cDNA synthesis kit and FastStart Essential DNA Green Master (Roche Life Science, Risch-Rotkreuz, Switzerland) respectively, according to the manufacturer’s protocol.

Nuclear cytoplasmic fractionation

Subcellular fractionation from fresh tissue was based on the protocol described by Baghirova et al. After fractionation, it was cross-checked by Western blotting with the corresponding loading control GAPDH for cytoplasmic and lamin for nuclear loading control.

Detection of serum β-catenin

Serum β-catenin was detected by ELISA using mouse β-catenin (β-cat) ELISA kit (CSB-E11307m; Cusabio) following the manufacturer’s protocol.

Statistical analysis

To find out whether TMX treatment had any significant effect, the t-test was performed between carcinogen control group and TMX treatment group, where P < 0.05, P < 0.005 and P < 0.0001 were considered as statistically significant. Data were represented as mean with standard deviation (SD) of at least three different experiments.

Results

Modulation of biochemical and hematological parameters

The haematological and biochemical parameters tell us whether TMX treatment could impart chemo-protection to the mice whose health deteriorated due to the malignant
condition induced by skin carcinogenesis. Increased levels of WBC and PLT count was normalized when TMX was administered at the non-toxic dosage to the carcinogen-treated mice. RBC and HGB levels were also modulated in a way that it became comparable to normal (Table 1). A similar trend of TMX-mediated normalization of elevated biochemical parameters was observed ($P < 0.001$) in comparison with carcinogen control (Table 1).

**Survivability of mice after treatment with TMX**

Survivability of mice on being treated with TMX was significantly increased in comparison to carcinogen control (Figure 1b). An increase in the survivability of carcinogen-exposed mice is an indication of the therapeutic efficacy of this natural compound.

**Phase-II detoxifying enzymes, LPO and ROS**

It was observed that carcinogen exposure caused augmentation of endogenous LPO and ROS levels in the mouse skin and liver, whereas in the TMX-treated sample an abatement of these two parameters was observed (Table 2). Similarly, antioxidative enzymes which were suppressed due to carcinogenic exposure increased in a significant manner ($P < 0.0001$) following TMX treatment in the same set of samples.

**Development of skin carcinogenesis by DMBA and croton oil**

The gradual progression of skin carcinogenesis was initiated with the appearance of papilloma(s) after the sixth week of the first carcinogen application. To study the progression of carcinogenesis, we collected papillomas from two animals at different time points and the experiment was repeated thrice. The histology was analysed by H&E staining and confirmed by an expert pathologist. Our analysis revealed that there was a mild to moderate hyperplasia around the sixth week by the thickening of the epithelial layer. Progression to the dysplastic stage (severe) was noted around the 14th week. The disordered cellular stratification and increased nuclear: protoplasm ($n/p$) ratio exhibited the characteristic signature of the dysplastic stage. Thereafter, the progression to well-differentiated carcinoma in situ around the 20th week was characterized by well-developed keratinization with distinct pearl body and moderate atypia (Figure 1c).

**Evaluation of restrictive potential of TMX**

The incidence of papilloma, i.e. tumour growing exophytically from the dorsal area, was observed around the 6th week after the first application of the carcinogen, whereas the time of incidence was significantly delayed, around the 14th week in the treated mice. Table 3 provides data on the incidence and inhibition of multiplicity of papillomas in the experimental groups at the 14th and 20th week, when well-differentiated carcinoma was observed in the CC group. It was also observed that the incidence of papilloma in the group which received TMX treatment was reduced by 50% with 79% inhibition of multiplicity at the end of 14th week and 55.5% with 80.8% inhibition of multiplicity at the end of 20th week in the CC group. It was also observed that TMX treatment significantly delayed the time of incidence of papilloma in the experimental groups at the 14th and 20th week, whereas well-differentiated carcinoma was observed in the CC group. There was thickening of the epidermal lining along with the formation of keratin pearl body and abnormally shaped cells called atypia in the CC group, which started around the 14th week and progressed into well-differentiated carcinoma around the 20th week is the prominent feature of invasion. In the treated samples, formation of pearl body was absent and a significantly lesser percentage of atypia was seen for both time points.

**Effect of TMX on inflammatory and angiogenic markers**

It was found from a previous analysis that TMX confers protective potential to mice during the progression of

### Table 2. Detoxifying enzymes, endogenous LPO and reactive oxygen species (ROS) level in liver and skin tissue

<table>
<thead>
<tr>
<th>Group</th>
<th>Sample: Liver</th>
<th>Sample: Skin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>GSH (nmol/mg)</td>
<td>GST (nmol/mg)</td>
</tr>
<tr>
<td>NC</td>
<td>3 (±0.4)</td>
<td>5 (±1)</td>
</tr>
<tr>
<td>CC</td>
<td>0.75 (±0.6)</td>
<td>2.15 (±0.86)</td>
</tr>
<tr>
<td>CT</td>
<td>4.72 (±1)*</td>
<td>12 (±1)*</td>
</tr>
<tr>
<td>NC</td>
<td>2 (±0.6)</td>
<td>3 (±1)</td>
</tr>
<tr>
<td>CC</td>
<td>0.89 (±0.8)</td>
<td>1.75 (±0.8)</td>
</tr>
<tr>
<td>CT</td>
<td>4.97 (±0.7)*</td>
<td>6.15 (±0.3)*</td>
</tr>
</tbody>
</table>

*Significant difference in the CT group is found from the CC group considering $P < 0.0001$. Values represent ± SEM of six samples in each group.
DMBA/croton oil-induced skin carcinogenesis. The underlying factors that impact their role in providing protection are the pro- and anti-inflammatory markers along with the angiogenic markers. In the present study, we found that TMX treatment of carcinogen-exposed mice resulted in significant downregulation of pro-inflammatory factors and angiogenic markers like IL-4, IL-1β, IL-6 and IL-18, VEGF, MMP-2 and MMP-9, and upregulation of anti-inflammatory factors like IL-10 ($P < 0.05$) in comparison to the CC group (Figure 2a). Therefore, these factors reinforce the preventive efficacy of TMX during the progression of induced carcinogenesis.

**Role of TMX on cellular proliferation**

Evaluation of the effect of TMX on the proliferation of skin tissue was analysed by IHC of this proliferation marker. The percentage of proliferative cells (dark-brown
Table 4. Effect of TMX on the relative risk due to cell proliferation and relative protection from apoptosis during skin carcinogenesis

<table>
<thead>
<tr>
<th>Group</th>
<th>Incidence of proliferative cells (%; ± SEM)</th>
<th>Relative risk factor (RRF)</th>
<th>Incidence of apoptotic cells (%; ± SEM)</th>
<th>Relative protective factor (RPF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>12 ± 0.7</td>
<td>–</td>
<td>27 ± 0.6</td>
<td>–</td>
</tr>
<tr>
<td>Carcinogen control (14th week)</td>
<td>80.24 ± 0.4</td>
<td>6.66</td>
<td>19.47 ± 2</td>
<td>0.7</td>
</tr>
<tr>
<td>TMX-treated (14th week)</td>
<td>20.21 ± 2</td>
<td>1.68**</td>
<td>50.49 ± 5</td>
<td>1.87**</td>
</tr>
<tr>
<td>Carcinogen control (20th week)</td>
<td>90.5 ± 3</td>
<td>7.5</td>
<td>12 ± 1</td>
<td>0.4</td>
</tr>
<tr>
<td>TMX-treated (20th week)</td>
<td>22.1 ± 2</td>
<td>1.83**</td>
<td>61.5 ± 2</td>
<td>2.22**</td>
</tr>
</tbody>
</table>

**P-value is <0.005. RRF, Incidence of proliferative cells after carcinogenic exposure/incidence of proliferative cells without carcinogenic exposure. RPF, Incidence of apoptotic cells after carcinogenic exposure/incidence of apoptotic cells without carcinogenic exposure.

Table 5. Incidence and frequency of papilloma in mouse skin at 14th and 20th week following exposure to DMBA/croton oil and treated with TMX correlated with an attributable risk

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Carcinogen control (14th week)</th>
<th>TMX-treated (14th week)</th>
<th>Carcinogen control (20th week)</th>
<th>TMX-treated (20th week)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RRF</td>
<td>6.66</td>
<td>1.68**</td>
<td>7.5</td>
<td>1.83</td>
</tr>
<tr>
<td>RPF</td>
<td>0.7</td>
<td>1.87**</td>
<td>0.4</td>
<td>2.22</td>
</tr>
<tr>
<td>Attributable risk (AR; %)</td>
<td>89.4</td>
<td>–11.3**</td>
<td>94.6</td>
<td>–17.5**</td>
</tr>
<tr>
<td>Incidence of papilloma (IP; %)</td>
<td>95</td>
<td>32</td>
<td>96</td>
<td>35</td>
</tr>
<tr>
<td>Multiplicity of papilloma (MP)</td>
<td>4.8 ± 0.2</td>
<td>1.8 ± 1</td>
<td>4.9 ± 0.1</td>
<td>1.9 ± 2</td>
</tr>
</tbody>
</table>

**P-value is <0.005. AR = ((RRF – RPF)/RRF) × 100. IP = ((Incidence of papilloma in CC – incidence of papilloma in treated)/(Incidence of papilloma in CC)) × 100. MP = ((No. of papilloma/mouse in CC – no. of papilloma/mouse in treated)/(No. of papilloma/mouse in CC)) × 100.

nucleated cells) was determined from the total number of nuclei at ten randomly chosen microscopic fields of skin lesion. A significant (P < 0.0001) reduction in the expression of proliferating cell nuclear antigen (PCNA) was observed for the CT group compared to the carcinogen control group for both the 14th and 20th weeks of treatment (Figure 2b).

Induction of apoptosis in skin tissue

The framework of drug-induced cell death helps reinforce the mechanism by which the malignancy burden is reduced. The percentage of apoptotic cells (dark-brown nucleated cells) was determined from the total number of nuclei counted at ten randomly chosen microscopic fields of skin lesion. A significant increase (P < 0.0001) in the percentage of apoptotic cells was found by TUNEL assay in the epithelial region in the CT group of samples in contrast to the CC group. Therefore, carcinogenesis is restricted in the skin tissue by restricting cell proliferation and induction of apoptosis for both the 14th and 20th weeks of TMX treatment (Figure 2c).

Mechanisms of induction of apoptosis

Increased BAX/BCL-2 ratio is a well-known marker of the intrinsic pathway of apoptosis. Therefore, to examine whether TMX could induce apoptosis by an intrinsic pathway, here the effect of TMX on BAX/BCL-2 was examined. A significant increase in the ratio in CT for both the 14th and 20th weeks was observed in comparison to CC, and it was comparable to NC where P < 0.0001 (Figure 2d).

Risk assessment

The relative risk factor (RRF) in the carcinogen control group at 14 and 20 weeks due to cell proliferation was 6.66 and 7.5 respectively, whereas in groups receiving TMX treatment it was significantly lower (1.68 and 1.83 respectively). TMX treatment caused a significant increase in the relative protective factor (RPF) which was due to increased apoptosis. Similarly, there was a significant decrease in relative risk factor (RRF) upon TMX treatment which was due to decreased proliferation. In the carcinogen control group, the values of RPF were 0.7 and 0.4, which were significantly increased as a result of TMX treatment to 1.87 and 2.22 for the two time points studied respectively (Tables 4 and 5). The attributable risk (AR) can be calculated on account of the incidence of papilloma produced upon exposure to DMBA and croton oil with or without any type of intervention. It was noted that AR in CC after the 14th and 20th weeks was 89.4% and 94.6% respectively. This had reduced to –11.3% and –17.5% respectively, after TMX treatment (Tables 4 and 5), which is indicative of the chemopreventive effect of the xanthone.

Role of TMX on modulation of cancer stem cell markers

CSCs are a small subpopulation of tumour cells with capabilities of self-renewal, differentiation, tumorigenicity.
when transplanted into a host and are the prime reason for drug resistance and metastasis. The cell-surface marker CD44 is often used to identify the CSC subset with aggressive characteristics like proliferation, migration, angiogenesis, etc. It is reported that a regulatory network between the Wnt/β-catenin pathway and CD44 controls the CSC properties in cancer. It has been suggested that the initial activation of Wnt/β-catenin signalling by APC loss is further enhanced by the stabilization of the oncogenic K-RAS protein. Therefore, for a more detailed study on the molecular mechanism, we evaluated whether TMX could modulate the CSC population. Our data as validated by both IHC and Western blot analysis delineated that expression of CD44, B-catenin and KRAS is significantly reduced, while APC, GSK-3β Sfrp1/2, P-53, and P21 are significantly upregulated in the treated condition in comparison with the CC group (Figure 3 a–c).

**Role of TMX on mRNA**

The change in the transcriptional level reinforced that alteration in expression was undoubtedly owing to modulation in the mRNA level. TMX treatment significantly upregulated markers APC, GSK3β, which are the regulators of β-catenin, along with the other two important regulators, SFRP1 and SFRP2. Conversely significant
downregulation of β-catenin and KRAS was also observed \( P < 0.0001 \) (Figure 3d).

**Role of TMX on β-catenin**

In the CC group, we observed highly upregulated nuclear β-catenin whereas significantly downregulated cytoplasmic β-catenin. Interestingly, upon TMX treatment, there was a significant increase in the cytoplasmic fraction of β-catenin and a decrease in the nuclear fraction as degradation of β-catenin occurs in the cytoplasm, thereby downregulating the transcription of several downstream oncogenes participating in carcinogenesis (Figure 3e).

**Correlation with carcinogenesis progression and serum β-catenin**

Serum-level β-catenin was observed to increase sequentially with the progression of carcinogenesis in the 6th, 14th and 20th weeks in the CC group. TMX treatment showed an almost comparable level of serum β-catenin to NC at each time point up to the 20th week (Figure 3f).

**Discussion and conclusion**

Polyphenols exhibit antioxidant activity by two main pathways, either by scavenging radicals to circumvent the cellular damage by ROS or by acting as molecules which can avert ROS production32. Antioxidants counteract oxidative stress, either enzymatically (vitamin C or E, or β-carotene) or non-enzymatically (superoxide dismutase), catalase or glutathione peroxidase to protect the cell organelles. Several epidemiological studies have demonstrated that changes in lifestyle and dietary habits could prevent or reduce cancer incidence33. In this study, we observed that TMX imparts cytoprotection against stress imparted by carcinogen treatment by upregulating phase-II detoxifying enzymes, and improving hematological and biochemical parameters. Increased levels of Wnt/β-catenin due to carcinogenic changes lead to overexpression of inflammatory cytokines like IL-4, IL-6, IL-1β and IL-18. Other molecules whose upregulation has been linked to increased levels of β-catenin are VEGF, MMP-2 and MMP-9, as these are known to be a downstream transcriptional target of β-catenin. Therefore, β-catenin is one of the central regulators in carcinogenesis34,35. Our data show that TMX treatment significantly downregulates inflammatory cytokines IL-4, IL-6, IL-1β and IL-18, and angiogenic markers MMP-2, MMP-9 and VEGF. Apoptosis plays an important role in chemotherapeutic and chemopreventive potential. There are many naturally occurring chemopreventive agents whose mode of action is the induction of apoptosis in cancer cells35. The cell proliferation and apoptosis balance is a crucial factor for carcinogenesis36. AR was calculated by counting the number of proliferative and non-proliferative cells at the target site, i.e. skin lesion, with and without exposure to a carcinogen (normal), modifying the method described by Burnekreef37. A 0% AR indicates that the risk generated due to exposure to a carcinogen is completely nullified by the compound under study, or there is no risk. Values greater than 0, signify some risk depending on the extent. A negative value qualifies the compound to have cancer-preventive potential. In this study we observed that TMX could efficiently induce apoptosis and reduce AR% to –11.3 and –17.5 after treatment for 14th and 20th weeks in the skin carcinogenesis model, which is indicative of its chemopreventive potential. P-53 plays a key role in the regulation of apoptosis. P-53 is one of the major targets of the Wnt signalling pathway, where cytoplasmic degradation of β-catenin has a central role38. P-53 induces activation of SIAH-1 (E3 ubiquitin ligase), which causes ubiquitination of β-catenin enabling its degradation. P53-mediated degradation of β-catenin simultaneous with cell-cycle arrest may play a central role in chemoprevention39. Glycogen synthase kinase-3β (GSK3β) has a vital role in the Wnt signalling pathway. P-53 activation is induced by DNA damage, which in turn transactivates GSK-3β. This activation is driven by direct binding of P-53 and GSK-3β, and causes the translocation of the latter to the nucleus. GSK-3β transactivation by P-53 promotes responses to the latter, including an increase in the P-21 levels40. Almost 30% of metastatic tumours have activating mutations in KRAS and 70% of metastatic tumours have loss-of-function mutations in TP-53 (ref. 41). Similar results are observed in the present study in the CC group when compared to the NC group. β-Catenin is an important component in the cell membrane and plays a role in cell adhesion. Upon receiving carcinogenic stimulus cells direct the nuclear translocation of β-catenin and various factors to carry forward the process of carcinogenesis42. TMX treatment significantly decreases the serum level of β-catenin, which was found to be significantly upregulated in the CC group. TMX treatment also significantly downregulated the total β-catenin, KRAS and nuclear translocation of β-catenin, with a significant upregulation of APC, GSK-3b Sfrp1/2, P-53 and P-21.

In conclusion, this study establishes that TMX has a chemopreventive potential and it does so by mediating cytoplasmic degradation of β-catenin by P-53- and P-21-mediated pathways.

